Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-03-05
2003-04-29
Eyler, Yvonne (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S325000, C536S023500
Reexamination Certificate
active
06555340
ABSTRACT:
Throughout this application, various publications are referenced by author and date within the text. Full citations for these publications may be found listed alphabetically at the end of the experimental details sections for each experiment. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
BACKGROUND OF THE INVENTION
The Receptor for AGE (RAGE) is a member of the immunoglobulin superfamily of cell-surface molecules (1-2). Originally identified and characterized as a cellular receptor for glucose (aldose sugar)-modified proteins, or Advanced Glycation Endproducts (AGEs) (3-13), RAGE has subsequently been reported to interact with other ligands, in both settings of normal development and in Alzheimer's disease (14-16). In normal development, RAGE interacts with amphoterin, a polypeptide which mediates neurite outgrowth in cultured embryonic neurons. In those studies, either anti-RAGE F(ab′)
2
or soluble RAGE (sRAGE) inhibited neurite outgrowth on amphoterin-coated matrices, but not on matrices coated with other substrates such as laminin or poly-l-lysine (3). In later studies, RAGE was identified as a receptor on neurons and microglia for amyloid-&bgr;-peptide, a polypeptide linked to the pathogenesis of neuronal toxicity and death in Alzheimer's disease.
SUMMARY OF THE INVENTION
The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a)(i) and the peptide of step (a)(ii), and (c) comparing the amount of interaction measured in step (b) with the amount measured between the peptide of step (a)(i) and the peptide of step (a)(ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.
REFERENCES:
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5976832 (1999-11-01), Hitomi et al.
patent: WO9739121 (1997-10-01), None
patent: WO9739125 (1997-10-01), None
Baynes, J.W. (1991). Role of oxidative stress in development of complications in diabetes.Diabetes40:405-412.
Borchelt, D.R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate A&bgr;1-42/1-40 ratio in vitro and in vivo.Neuron17: 1005-1013.
Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.Am. J. Pathol.143(6):1699-1717.
Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications.Diabetes Care15(12):1835-1842.
Cai, X.-D., et al. (1993). Release of excess amyloid &bgr; protein from a mutant amyloid &bgr; protein precursor.Science259:514-516.
Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid &bgr;-protein in both transfected cells and transgenic mice.Nature Medicine3(1):67-72.
Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes.J. Biol. Chem.269:28929-28936.
Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing.J. Surg. Res.50:308-313.
Fu, M.-X., et al. (1996). The advanced glycation end product N&egr;-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions.J. Biol. Chem.271:9982-9986.
Giardino, I., et al. (1994). Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity.J. Clin. Invest.94:110-117.
Gibbons, G.H. and V.J. Dzau. (1996). Molecular therapies for vascular diseases.Science272:689-693.
Hori, O., et al. (1995). The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin.J. Biol. Chem.270:25752-25761.
Khoury, J.E., et al., (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors.J. Biol. Chem.269:10197-10200.
Kuo, Y-M., et al. (1996). Water-soluble A&bgr; (N-40, N-42) oligomers in normal and Alzheimer Disease brains.J. Biol. Chem.271(8):4077-4081.
Lander, H.M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21rasdependent mitogen-activated protein kinase pathway regulated by oxidant stress.J. Biol. Chem.272:17810-17814.
Ledesma, M.D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments.J. Biol. Chem.269(34):21614-21619.
Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.J. Biol. Chem.272:16498-16506.
Lorenzo, A. and B.A. Yanker (1994). &bgr;-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red.Proc. Nat. Acad. Sci. USA91:12243-12247.
Mattson, M.P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium.Brain Res.676:219-224.
Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-&bgr;2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway.J. Clin. Invest.98:1088-1094.
Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissues in diabetes mellitus.Am. J. Pathol.143(6):1649-1656.
Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.J. Biol. Chem.267:14998-15004.
Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.Arterioscl. Thromb. and Vasc. Biol.15(5):571-582.
Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.Nature Medicine4:1025-1031.
Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts.Circulation Supplement.Abstract 3079.
Reddy S., et al. (1995). N&egr;-(Carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.Biochemistry34:10872-10878.
Renard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats.Mol. Pharm.52:54-62.
Ritthaler, et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.Am. J. Pathol.146:688-694.
Roher, A.E., et al. (1996). Morphology and toxicity of A&bgr;-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease.J. Biol. Chem.271(343):20631-20635.
Schleicher, E.D., et al. (1997). Increased accumulation of the glycoxidation product N&egr;-(Carboxymethyl) lysine in human tissues in diabetes and aging.J. Clin. Invest.99:457-468.
Schmidt, A.M., et al. (1995). Advanced glycation endp
Schmidt Ann Marie
Stern David
Andres Janet L.
Cooper & Dunham LLP
Eyler Yvonne
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Nucleic acid encoding bovine extracellular rage binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid encoding bovine extracellular rage binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid encoding bovine extracellular rage binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3008493